3P Biopharmaceuticals, a Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has appointed Iker Portugal as chief financial officer.
 
Portugal is an experienced financial manager and joins 3P Biopharmaceuticals with the aim of boosting the company´s growth plans. With this new addition to the management team, 3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.
 
Portugal comes to 3P with more than 20 years of financial leadership experience. He started his career in 1996 in financial consulting and investment banking and over his extended career he has held a wide range of corporate financial responsibilities, including Investor Relations, Planning & Control or Capital Markets in companies such as the airline technology provider Amadeus, and CFO for the food & drink manufacturer JGC Group. Since mid-2019, and prior to joining 3P, Portugal has been a consultant and investor in a Biotech start-up.
 
“I come to 3P Biopharmaceuticals very excited about the opportunity. 3P is a fast-growing company in an expanding sector: Biotech. Therefore, the opportunity for all of us is unique. The fact that our majority partner is Keensight Capital is definitely a plus, as it brings, on the one hand, the expertise of a large fund specialized in Healthcare, and also the capital support that will allow us to grow faster and take advantage of growth opportunities that I am sure will arise,” explained Portugal.